Novartis adquire desenvolvedora de tratamento contra câncer de medula óssea por US$ 2,9 bilhões

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Novartis adquire desenvolvedora de tratamento contra câncer de medula óssea por US$ 2,9 bilhões

/jornal/2024/02/novartis-adquire-desenvolvedora-de-tratamento-contra-cancer-de-medula-ossea-por-us-2-9-bilhoes/

Novartis (BOV:N1VS34)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Novartis Charts.

Novartis (BOV:N1VS34)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Novartis Charts.

News

More News Articles

Cassava Sciences

Enzolytics (PK)

Moon Equity (PK)

Enanta Pharmaceuticals

Anavex Life Sciences

Brookmount Explorations (PK)

Digital Brand Media and ... (PK)

Global Developments (PK)

AMC Entertainment

ERHC Energy (CE)

Good Vibrations Shoes (PK)

Kraig Biocraft Laborator... (QB)

Lightwave Logic

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions